AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
HC Wainwright & Co. reiterated its coverage of Co-Diagnostics with a Neutral recommendation. Analysts forecast an average one-year price target of $2.04/share, a 482.52% increase from its latest closing price of $0.35/share. The projected annual revenue for Co-Diagnostics is $2MM, a 201.25% increase, and the projected annual non-GAAP EPS is 0.38.

Daily stocks & crypto headlines, free to your inbox
Could you provide some quality stocks that are best suited for long-term retirement investing?
Which U.S. stocks suit long-term holding with dividends beating inflation?
How do employee numbers compare among Magnificent 7 over the past decade?
What powerful indicators do day traders use?
Comments
No comments yet